Checkpoint inhibitors for triple-negative breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Giuseppe Curigliano, MD, PhD, from Istituto Europeo di Oncologia, Milan, Italy, discusses the value of immune checkpoint inhibitors for the treatment of patients with metastatic triple-negative breast cancer. Multiple checkpoint inhibitors are currently in clinical development for this patient group, including anti-PD-1 antibody pembrolizumab, anti-PD-1 antibody nivolumab and anti-PD-L1 antibody atezolizumab.